Elanco Animal Health IncorporatedELAN
NYSE•Healthcare•Drug Manufacturers - Specialty & Generic
Analyze revenue and earnings growth — the core drivers of long-term shareholder returns.
TTM revenue reached $4.89B, growing 10.5% year-over-year. TTM net income stood at $-242.00M (164.9% contraction). Quarterly EBITDA was $463.00M and operating income was $291.00M. Consistent revenue and earnings growth are the primary drivers of long-term shareholder returns. Analyze ELAN growth trends across revenue, EBITDA, operating income, and net income.
Revenue and earnings growth across quarters